- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05389696
Clinical Trial to Evaluate Pharmacokinetic Characteristics of MIT-001 After SC Administration in Healthy Subjects
August 22, 2023 updated by: MitoImmune Therapeutics
Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Characteristics of MIT-001 After Subcutaneous and Intravenous Administration in Healthy Subjects
- Part 1 Randimization, Double blinded, Placebo controlled, Dose escalation(10mg, 20mg, 40mg) of MIT-001 SC or IV single administration to evaluate safety, tolerability and PK in healthy adult.
- Part2 Randimization, Double blinded, Placebo controlled, MIT-001 SC multiple administration for 7days (20mg & 40mg) to evaluate safety, tolerability and PK in healthy adult.
Study Overview
Status
Completed
Conditions
Detailed Description
This is a Phase 1, randomized, double-blind, placebo-controlled, single and multiple dose, dose escalation clinical trial in 40 healthy subjects.
This study consists of part 1(single dose for group 1, 2, 3) and part 2(multiple dose for 7 days to group 1 and 2).
Subjects will be assigned in 6:2 allocation to receive active or placebo treatments.
The purpose of this clinical trial is to evaluate the safety, tolerability and pharmacokinetic properties of MIT-001 after single and multiple subcutaneous administration in healthy adults and to compare IV administration.
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 03080
- Seoul National University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- A healthy adult between 19 and 45 at the time of screening
A person who weigh 55.0 kg or more and 90.0 kg or less at the time of screening and have a body mass index (BMI) of 18.0 or more and 27.0 or less
☞ BMI (kg/m2) = Weight (kg) / {Height (m)}2
- A person who voluntarily decides to participate after hearing and fully understanding the detailed explanation of this clinical trial and consents in writing before the screening procedure
- A person suitable as a test subject for this study when judged by the investigator through physical examination, clinical laboratory examination, questionnaire, etc.
Exclusion Criteria:
- Clinically significant liver, kidney, nervous system, immune system, respiratory system, endocrine system disease, blood/tumor disease, cardiovascular disease, mental disease (mood disorder, obsessive-compulsive disorder, etc.) or a history of above diseases
- A person with a history of hypersensitivity or clinically significant hypersensitivity to clinical investigational drugs, drugs containing the same class of ingredients, and other drugs (aspirin, antibiotics, etc.)
- At screening, QTc > 450 ms on ECG or other clinically significant findings
- A person with AST and ALT exceeding 1.5 times the upper limit of the normal range during screening
- A person with eGFR of less than 60 mL/min/1.73m2 measured using the CKD EPI formula in clinical laboratory tests at screening
- At screening, systolic blood pressure > 160 mmHg or < 90 mmHg, or diastolic blood pressure > 100 mmHg or < 50 mmHg
- A person with a history of drug abuse or who have tested positive for drugs of abuse in urine drug screening tests
- A person who has taken any prescription drugs or herbal medicines within 2 weeks before the first scheduled administration date, or have taken any over-the-counter (OTC), health functional food, or vitamin preparations within 1 week In cases where it is reasonable, they can participate in the clinical trial) or those who are expected to take it
- A person who has taken drugs that induce or inhibit drug metabolizing enzymes, such as barbiturates, within 1 month before the first scheduled administration date
- A person who has participated in other clinical trials or bioequivalence studies within 6 months prior to the scheduled first administration date and received the investigational drug or bioequivalence study drug
- A person who has donated whole blood within 2 months before the first scheduled dose or donated component blood within 1 month, or received blood transfusion within 1 month before the first scheduled dose
- A person who continuously drinks alcohol (more than 21 units/week, 1 unit = 10 g of pure alcohol (≒ 1 glass of soju or 250 mL of beer)) or cannot abstain from alcohol during the clinical trial period
- Smokers (However, if you quit smoking 3 months before the first scheduled dose, you can be selected as a test subject)
- A person who has consumed caffeine-containing foods (coffee, tea (black tea, green tea, etc.), carbonated drinks, coffee milk, nourishing drinks, etc.) within 24 hours of hospitalization for clinical trials and those who cannot refrain from consuming them during hospitalization
- A person who does not use the following medically acceptable contraceptive methods for 1 month from participation in the clinical trial to the last administration of the investigational drug A. Use of an intrauterine device (copper loop, hormone-containing intrauterine system) with a proven rate of pregnancy failure in the spouse (or partner) B. Concomitant use of either a spermicide or a parenteral hormonal contraceptive with a barrier contraceptive method (male or female) C. Surgery of you or your partner (vasectomy, fallopectomy/ligation, hysterectomy, etc.) D. Use of a cervical cap or contraceptive diaphragm with a male condom
- Pregnant or lactating women
- A person who judged the investigator to be inappropriate to participate in the clinical trial due to other reasons
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part1. Group1. MIT-001 SC 10mg
Single subcutaneous administration of 10mg MIT-001 or placebo
|
Single subcutaneous administration and Blood collection
Other Names:
|
Experimental: Part1. Group2. MIT-001 SC 20mg
Single subcutaneous administration of 20mg MIT-001 or placebo
|
Single subcutaneous administration and Blood collection
Other Names:
|
Experimental: Part1. Group3. MIT-001 SC 40mg and IV 40mg
Single subcutaneous administration of 40mg MIT-001 or placebo and then signle intravenous administration of 40mg MIT-001 or placebo
|
Single subcutaneous administration and then single intravenous administration after 2 weeks.
In addition Blood collection is conducted as scheduled.
Other Names:
|
Experimental: Part2. Group1: MIT-001 SC 20mg
Multiple subcutaneous administration of 20mg MIT-001/day or placebo for 7days
|
Multiple subcutaneous administration for 7 days and then blood collection
Other Names:
|
Experimental: Part2. Group2: MIT-001 SC 40mg
Multiple subcutaneous administration of 40mg MIT-001/day or placebo for 7days
|
Multiple subcutaneous administration for 7 days and then blood collection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PK_Cmax_Part1 Group 1&2
Time Frame: Part1. Group 1&2: Before SC administration(Day0, 0hour) to 144hour after administration 16 points.
|
Part 1, Group 1,2: Cmax
|
Part1. Group 1&2: Before SC administration(Day0, 0hour) to 144hour after administration 16 points.
|
PK_Cmax_Part1 Group 3
Time Frame: Part1. Group 3_Before SC administration(Day0, 0hour) to 144hour 16 points and then Before IV administration on 15th day(0hour) to 144hour after IV administration 17points.
|
Part 1, Group 3: Cmax
|
Part1. Group 3_Before SC administration(Day0, 0hour) to 144hour 16 points and then Before IV administration on 15th day(0hour) to 144hour after IV administration 17points.
|
PK_AUClast_Part1 Group 1&2
Time Frame: Part1. Group 1&2_Before SC administration(Day0, 0hour) to 144hour after administration 16 points.
|
Part1, Group 1&2: AUClast
|
Part1. Group 1&2_Before SC administration(Day0, 0hour) to 144hour after administration 16 points.
|
PK_AUClast_Part1 Group 3
Time Frame: Part1. Group 3_Before SC administration(Day0, 0hour) to 144hour 16 points and then Before IV administration on 15th day(0hour) to 144hour after IV administration 17points.
|
Part 1, Group 3: AUClast
|
Part1. Group 3_Before SC administration(Day0, 0hour) to 144hour 16 points and then Before IV administration on 15th day(0hour) to 144hour after IV administration 17points.
|
PK_AUCinf_Part 1, Group 1&2
Time Frame: Part1. Group 1&2_Before SC administration(Day0, 0hour) to 144hour after administration 16 points.
|
Part 1, Group 1&2: AUCinf
|
Part1. Group 1&2_Before SC administration(Day0, 0hour) to 144hour after administration 16 points.
|
PK_AUCinf_Part 1, Group 3
Time Frame: Part1. Group 3_Before SC administration(Day0, 0hour) to 144hour 16 points and then Before IV administration on 15th day(0hour) to 144hour after IV administration 17points.
|
Part 1, Group 3: AUCinf
|
Part1. Group 3_Before SC administration(Day0, 0hour) to 144hour 16 points and then Before IV administration on 15th day(0hour) to 144hour after IV administration 17points.
|
PK_Tmax_Part 1, Group 1&2
Time Frame: Part1. Group 1&2_Before SC administration(Day0, 0hour) to 144hour after administration 16 points.
|
Part 1, Group 1&2: Tmax
|
Part1. Group 1&2_Before SC administration(Day0, 0hour) to 144hour after administration 16 points.
|
PK_Tmax_Part 1, Group 3
Time Frame: Part1. Group 3_Before SC administration(Day0, 0hour) to 144hour 16 points and then Before IV administration on 15th day(0hour) to 144hour after IV administration 17points.
|
Part 1, Group 3: Tmax
|
Part1. Group 3_Before SC administration(Day0, 0hour) to 144hour 16 points and then Before IV administration on 15th day(0hour) to 144hour after IV administration 17points.
|
PK_t1/2_Part 1, Group 1&2
Time Frame: Part1. Group 1&2_Before SC administration(Day0, 0hour) to 144hour after administration 16 points.
|
Part 1, Group 1&2: t1/2
|
Part1. Group 1&2_Before SC administration(Day0, 0hour) to 144hour after administration 16 points.
|
PK_t1/2_Part 1, Group 3
Time Frame: Part1. Group 3_Before SC administration(Day0, 0hour) to 144hour 16 points and then Before IV administration on 15th day(0hour) to 144hour after IV administration 17points.
|
Part 1, Group 3: t1/2
|
Part1. Group 3_Before SC administration(Day0, 0hour) to 144hour 16 points and then Before IV administration on 15th day(0hour) to 144hour after IV administration 17points.
|
PK_Vd/F_Part 1, Group 1&2
Time Frame: Part1. Group 1&2_Before SC administration(Day0, 0hour) to 144hour after administration 16 points.
|
Part 1, Group 1&2: Vd/F
|
Part1. Group 1&2_Before SC administration(Day0, 0hour) to 144hour after administration 16 points.
|
PK_Vd/F_Part 1, Group 3
Time Frame: Part1. Group 3_Before SC administration(Day0, 0hour) to 144hour 16 points and then Before IV administration on 15th day(0hour) to 144hour after IV administration 17points.
|
Part 1, Group 3: Vd/F
|
Part1. Group 3_Before SC administration(Day0, 0hour) to 144hour 16 points and then Before IV administration on 15th day(0hour) to 144hour after IV administration 17points.
|
PK_CL/F_Part 1, Group 1,2
Time Frame: Part1. Group 1&2_Before SC administration(Day0, 0hour) to 144hour after administration 16 points.
|
Part 1, Group 1,2: CL/F
|
Part1. Group 1&2_Before SC administration(Day0, 0hour) to 144hour after administration 16 points.
|
PK_CL/F_Part 1, Group 3
Time Frame: Part1. Group 3_Before SC administration(Day0, 0hour) to 144hour 16 points and then Before IV administration on 15th day(0hour) to 144hour after IV administration 17points.
|
Part 1, Group 3: CL/F
|
Part1. Group 3_Before SC administration(Day0, 0hour) to 144hour 16 points and then Before IV administration on 15th day(0hour) to 144hour after IV administration 17points.
|
PK_MRT_Part 1, Group 1&2
Time Frame: Part1. Group 1&2_Before SC administration(Day0, 0hour) to 144hour after administration 16 points.
|
Part 1, Group 1,2: MRT
|
Part1. Group 1&2_Before SC administration(Day0, 0hour) to 144hour after administration 16 points.
|
PK_MRT_Part 1, Group 3
Time Frame: Part1. Group 3_Before SC administration(Day0, 0hour) to 144hour 16 points and then Before IV administration on 15th day(0hour) to 144hour after IV administration 17points.
|
Part 1, Group 3: MRT
|
Part1. Group 3_Before SC administration(Day0, 0hour) to 144hour 16 points and then Before IV administration on 15th day(0hour) to 144hour after IV administration 17points.
|
PK_F_Part1, Group1,2
Time Frame: Part1. Group 1&2_Before SC administration(Day0, 0hour) to 144hour after administration 16 points.
|
Part 1, Group 1,2: F
|
Part1. Group 1&2_Before SC administration(Day0, 0hour) to 144hour after administration 16 points.
|
PK_F_Part1, Group3
Time Frame: Part1. Group 3_Before SC administration(Day0, 0hour) to 144hour 16 points and then Before IV administration on 15th day(0hour) to 144hour after IV administration 17points.
|
Part 1, Group 3: F
|
Part1. Group 3_Before SC administration(Day0, 0hour) to 144hour 16 points and then Before IV administration on 15th day(0hour) to 144hour after IV administration 17points.
|
PK_Part2_Cmax
Time Frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
Part 2: Cmax
|
Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
PK_Part2_Cmin
Time Frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
Part 2: Cmin, Cavg, AUCtau, Tmax, t1/2, Vd/F, CL/F, Cmax,ss, Cmin,ss, Cavg,ss, AUCtau,ss, Tmax,ss, t1/2,ss, Vdss/F, CLss/F, PTF, Rac
|
Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
PK_Part2_Cavg
Time Frame: Par2_Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
Part 2: Cavg
|
Par2_Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
PK_Part2_AUCtau
Time Frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
Part 2: AUCtau
|
Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
PK_Part2_Tmax
Time Frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
Part 2: Tmax
|
Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
PK_Part2_t1/2
Time Frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
Part 2: t1/2
|
Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
PK_Part2_Vd/F
Time Frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
Part 2: Vd/F
|
Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
PK_Part2_CL/F
Time Frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
Part 2: CL/F
|
Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
PK_Part2_Cmax,ss
Time Frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
Part 2: Cmax,ss
|
Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
PK_Part2_Cmin,ss
Time Frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
Part 2: Cmin,ss
|
Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
PK_Part2_Cavg,ss
Time Frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
Part 2: Cavg,ss
|
Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
PK_Part2_AUCtau,ss
Time Frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
Part 2: AUCtau,ss
|
Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
PK_Part2_Tmax,ss
Time Frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
Part 2: Tmax,ss
|
Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
PK_Part2_t1/2,ss
Time Frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
Part 2: _t1/2,ss
|
Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
PK_Part2_Vdss/F
Time Frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
Part 2: _Vdss/F
|
Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
PK_Part2_CLss/F
Time Frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
Part 2: _VCLss/F
|
Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
PK_Part2_PTF
Time Frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
Part 2: _PTF
|
Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
PK_Part2_Rac
Time Frame: Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
Part 2: _Rac
|
Part2: Before SC administration(Day0, 0hour) to 24hour 13points, Day5 0hour, Day6 0hour and then Day7 0hour to 216hour after SC administration 17points
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: SeungHwan Lee, MD, Seoul National University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 13, 2022
Primary Completion (Actual)
February 13, 2023
Study Completion (Actual)
April 28, 2023
Study Registration Dates
First Submitted
May 10, 2022
First Submitted That Met QC Criteria
May 20, 2022
First Posted (Actual)
May 25, 2022
Study Record Updates
Last Update Posted (Actual)
August 24, 2023
Last Update Submitted That Met QC Criteria
August 22, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- MIT001-FD-SC01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heathly Subjects
-
National Institute of Neurological Disorders and...CompletedMovement Disorders | Heathly SubjectsUnited States
-
Ohio State UniversityCompleted
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
-
PfizerCompletedHealthy Adult Subjects and Healthy Elderly SubjectsBelgium
-
ImevaXCompletedHelicobacter Pylori Infected Subjects | Helicobacter Pylori Naive SubjectsGermany
-
Yuhan CorporationRecruitingAtopic Healthy Subjects | Adult Subjects With Mild Allergic DiseasesKorea, Republic of
-
Yuhan CorporationCompletedAtopic Healthy Subjects | Adult Subjects With Mild Allergic DiseasesKorea, Republic of
-
AdjuTec Pharma ASCTC Clinical Trial Consultants ABNot yet recruiting
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Recruiting
-
Shouyao Holdings (Beijing) Co. LTDNot yet recruiting
Clinical Trials on Single subcutaneous administration and Blood collection
-
University of OxfordMahidol University; Li Ka Shing Foundation; Chiangrai Prachanukroh HospitalCompleted
-
Jena University HospitalUnknownImmunization; InfectionGermany
-
Children's Oncology GroupRecruitingTeratoma | Choriocarcinoma | Germinoma | Germ Cell Tumor | Yolk Sac Tumor | Embryonal Carcinoma | Mixed Germ Cell Tumor | Late Effects | Pediatric Germ Cell TumorUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Acute Lymphoblastic LeukemiaUnited States
-
GlaxoSmithKlineCompletedAsthmaUnited Kingdom
-
Sichuan UniversityRecruitingHepatocellular Carcinoma | Gastric Cancer | Non-Small-Cell Lung Cancer | Colon Rectal CancerChina
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingHypothyroidismNetherlands
-
University Hospital, ToulouseCompleted
-
MegalabsNot yet recruiting
-
PfizerActive, not recruiting